Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Eunice S. Wang, MD, Richard Aplenc, MD PhD, Deborah Chirnomas, Michael John Dugan, MD, Salman Fazal, MD, Swaminathan Iyer, Tara L Lin, MD, Sucha Nand, MD, Kristen J Pierce, Paul J Shami, MD, Jennifer J Vermette, Camille N Abboud, MD

Blood (2018) 132 (Supplement 1): 3979.

https://doi.org/10.1182/blood-2018-99-110804

Published: 2018

Journal Articles

Prediction of Hepatic Complications after Allogeneic Haemotopoetic Stem Cell Transplantation Using Liver and Spleen Stiffness Measurement

Georg-Nikolaus Franke, MD, Tina Weiße, MD, David Petroff, PhD, Sebastian Beer, MD, Christine Döhring, MD, Gerhard Behre, MD, Janett Fischer, Franziska Lindner, Johannes Wiegand, Volker Keim, MD, Dietger Niederwieser, MD, Thomas Karlas, MD

Blood (2018) 132 (Supplement 1): 2073.

https://doi.org/10.1182/blood-2018-99-111463

Published: 2018

Journal Articles

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Alessandro de Moura Almeida, MD, Helma Pinchemel Cotrim, PhD, Dayanne Costa Fonseca, MD, Dora Marcia Alencar, MD, Daniela Dourado Dutra, MD, Herbert Henrique de Melo Santos, MD, Monica Botura, MD, Marco Aurelio Salvino, PhD, Maria da Gloria Bomfim Arruda, PhD

Blood (2018) 132 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2018-99-120015

Published: 2018

Journal Articles

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Elie Traer, MD PhD, Eunice S. Wang, MD, Harry P. Erba, MD PhD, William Blum, MD, Cecilia Arana-Yi, MD, Callum M. Sloss, Kerry Culm-Merdek, Jeanette Towles, Patrick A. Zweidler-McKay, MDPhD, Daniel J. DeAngelo, MD

Blood (2017) 130 (Supplement 1): 1312.

https://doi.org/10.1182/blood.V130.Suppl_1.1312.1312

Published: 2017

Journal Articles

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

Jacqueline Baptista, RN, APN, Eris Tollkuci, PharmD, Sunita Nathan, MD, John J. Maciejewski, MD PhD, Melissa L. Larson, MD, Gorgun Akpek, MD MHS

Blood (2016) 128 (22): 5200.

https://doi.org/10.1182/blood.V128.22.5200.5200

Published: 2016

Journal Articles

Direct Oral Anticoagulants in Patients with Cirrhosis Appear Safe and Effective

Paul R Kunk, MD, Hampton Collins, MD, Surabhi Palkimas, Pharm D., Nicolas M Intagliata, MD, Hillary S. Maitland, MD MS

Blood (2016) 128 (22): 3827.

https://doi.org/10.1182/blood.V128.22.3827.3827

Published: 2016

Journal Articles

Single Agent Brentuximab As Bridging Therapy for Hodgkin Lymphoma Patients with Hepatic Impairment

Arjun Gupta, MD, Jan Petrasek, MD PhD, Shiraj Sen, MD PhD, Harris V. Naina, MD

Blood (2015) 126 (23): 5105.

https://doi.org/10.1182/blood.V126.23.5105.5105

Published: 2015

Journal Articles

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Lung-Ji Chang, PhD, Lujia Dong, MD, Jun Zhu, MD, Zhitao Ying, MD, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Yu-Qin Song, MD, Xiao-Pei Wang, MD, Yong-Qian Jia, MD, Ting Niu, MD PhD, Ting Liu, MDPhD, Ling Pan, MD, Zhuo-Gang Liu, MD, Tong Li, MD, Ying-Chun Li, MD, Kun Yao, MD, Xiaoyan Ke, MD PhD, Hongmei Jing, MD, Fang Bao, MD

Blood (2015) 126 (23): 264.

https://doi.org/10.1182/blood.V126.23.264.264

Published: 2015

Journal Articles

Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Mansoor N Saleh, MD, Gregory Cheng, James B Bussel, MD, Paul Burgess, Kalpana Bakshi, BS, MS, Andres Brainsky, MD, Christine K Bailey, PhD

Blood (2012) 120 (21): 2198.

https://doi.org/10.1182/blood.V120.21.2198.2198

Published: 2012

Journal Articles

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,

Mansoor N Saleh, MD, Gregory Cheng, MD, PhD, James B Bussel, MD, Paul Burgess, Lisa Marcello, BA, MS, Christine K Bailey, PhD, Andres Brainsky, MD

Blood (2011) 118 (21): 3296.

https://doi.org/10.1182/blood.V118.21.3296.3296

Published: 2011

Journal Articles

Evaluation of Hepatobiliary Parameters During Eltrombopag Treatment in Patients with Chronic Immune Thrombocytopenic Purpura.

Willis C. Maddrey, Gregory Cheng, Abderrahim Khelif, Susan L Wroblewski, Andres Brainsky

Blood (2009) 114 (22): 2410.

https://doi.org/10.1182/blood.V114.22.2410.2410

Published: 2009

NARROW

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prediction of Hepatic Complications after Allogeneic Haemotopoetic Stem Cell Transplantation Using Liver and Spleen Stiffness Measurement

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Bridging to Second Allogeneic Peripheral Blood Stem Cell Transplantation with Nelarabine in a Patient with Multiply Relapsed/Refractory T-Cell ALL

Direct Oral Anticoagulants in Patients with Cirrhosis Appear Safe and Effective

Single Agent Brentuximab As Bridging Therapy for Hodgkin Lymphoma Patients with Hepatic Impairment

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,

Evaluation of Hepatobiliary Parameters During Eltrombopag Treatment in Patients with Chronic Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only